CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

BACKGROUND: In metastatic clear cell renal cell carcinoma (ccRCC), different combination therapies, each including anti-PD-1 immune checkpoint blockade (ICB), are applied as first-line treatment. Robust predictive biomarkers for rational upfront therapy decisions are lacking, although they are urgen...

Descripción completa

Detalles Bibliográficos
Autores principales: Klümper, Niklas, Ralser, Damian J, Zarbl, Romina, Schlack, Katrin, Schrader, Andres Jan, Rehlinghaus, Marc, Hoffmann, Michèle J, Niegisch, Günter, Uhlig, Annemarie, Trojan, Lutz, Steinestel, Julie, Steinestel, Konrad, Wirtz, Ralph M, Sikic, Danijel, Eckstein, Markus, Kristiansen, Glen, Toma, Marieta, Hölzel, Michael, Ritter, Manuel, Strieth, Sebastian, Ellinger, Jörg, Dietrich, Dimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395367/
https://www.ncbi.nlm.nih.gov/pubmed/34446578
http://dx.doi.org/10.1136/jitc-2021-002949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395367/
https://www.ncbi.nlm.nih.gov/pubmed/34446578
http://dx.doi.org/10.1136/jitc-2021-002949

Ejemplares similares